Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
News and updates on ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) focus on its progress as a clinical stage oncology company developing therapies that address mechanisms of therapeutic resistance in cancer. ORIC regularly reports clinical data, operational milestones, and financial updates that are relevant to investors and observers following the ORIC stock and its development programs.
Recent news highlights include Phase 1b data for ORIC-944 (also referred to as rinzimetostat) in metastatic castration-resistant prostate cancer, where the company has discussed PSA responses, circulating tumor DNA reductions, and a safety profile described as compatible with long-term dosing when combined with androgen receptor inhibitors. ORIC also provides updates on preclinical findings for ORIC-944 in castration-sensitive prostate cancer models and KRAS G12C-mutant NSCLC and colorectal cancer models.
For enozertinib (ORIC-114), ORIC’s news flow includes late-breaking oral and poster presentations at major scientific meetings such as the ESMO Asia Congress. The company reports systemic and CNS activity in non-small cell lung cancer patients with EGFR exon 20, EGFR atypical (including PACC), and HER2 exon 20 mutations, including in patients with active brain metastases. These articles often detail objective response rates, disease control rates, intracranial responses, and safety observations from Phase 1b cohorts.
Corporate news items cover participation in healthcare conferences, strategic pipeline prioritization to focus on ORIC-944 and enozertinib, leadership appointments such as the creation of a Chief Technical Officer role, and capital raises via private placements and at-the-market programs. Financial press releases summarize quarterly results, research and development spending, and the company’s cash and investment position.
This news page aggregates ORIC’s press releases and related disclosures so readers can follow clinical trial readouts, program updates, corporate developments, and other material events affecting ORIC Pharmaceuticals and the ORIC ticker over time.
ORIC Pharmaceuticals (NASDAQ: ORIC) has secured a $125 million private placement financing through the sale of approximately 19.2 million shares at $6.50 per share, representing an 18% premium to its 10-day trailing VWAP. The financing, led by SR One with participation from notable investors including Point72, Viking Global Investors, and others, is expected to close on May 29, 2025.
The company will issue common stock and pre-funded warrants with an exercise price of $0.0001 per share. The proceeds, combined with existing cash reserves, are expected to fund operations into the second half of 2027, including through the anticipated primary endpoint readout from the first ORIC-944 Phase 3 registrational trial in prostate cancer.
- 59% PSA50 response rate (47% confirmed) and 24% PSA90 response rate (all confirmed) across all dose levels
- Safety profile shows majority of adverse events were Grade 1 or 2, with diarrhea being the most common side effect in 53% of patients
The company secured a $125 million private placement financing, extending cash runway into 2H 2027. ORIC plans to complete Phase 1b dose exploration by mid-2025, followed by dose optimization in 2H 2025, and aims to initiate its first global Phase 3 registrational trial in 1H 2026.
ORIC Pharmaceuticals (NASDAQ: ORIC), a clinical stage oncology company, has announced its participation in two major investor conferences in June 2025. The company will engage in fireside chats at:
- The Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 p.m. ET
- The Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 10:00 a.m. ET
Webcasts of both discussions will be accessible through ORIC's investor relations website and will remain available for replay for 90 days after the events.
ORIC Pharmaceuticals (NASDAQ: ORIC) has announced an upcoming presentation of initial data from their Phase 1b trial of ORIC-944. The trial evaluates the combination of ORIC-944 with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC).
The presentation will take place during a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. Investors can access the presentation through phone participation with pre-registration or via webcast through the company's website. The webcast recording will be available for 90 days after the presentation.
ORIC Pharmaceuticals (NASDAQ:ORIC) announced the granting of inducement equity awards to four new non-executive employees who joined the company in April 2025. The grants, approved on May 1, 2025, include 32,400 non-qualified stock options and 5,200 restricted stock units. The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The restricted stock units will vest in three equal annual installments. These grants were made under the company's 2022 Inducement Equity Incentive Plan and were approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals presented promising preclinical data for their drug ORIC-944 at the 2025 AACR Annual Meeting. The drug, a selective PRC2 inhibitor, showed significant potential in treating prostate cancer when combined with standard treatments.
Key findings include:
- Increased progression-free survival when combined with androgen receptor pathway inhibitors (ARPIs)
- Demonstrated both transcriptional and antitumor synergy with ARPIs
- Showed robust PRC2 inhibition and enhanced luminal cell state
- Prevented tumor adaptation through chromatin remodeling
The drug is currently in Phase 1b trials, being tested in combination with two established treatments: ERLEADA (apalutamide) and NUBEQA (darolutamide). Chief Scientific Officer Lori Friedman highlighted ORIC-944's potential to be a best-in-class treatment across different stages of prostate cancer.
This development represents a significant step forward in addressing therapeutic resistance in prostate cancer treatment, positioning ORIC-944 as a promising candidate for both castration-resistant and castration-sensitive prostate cancer.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced new employee inducement grants approved on April 1, 2025. The company granted 50,600 non-qualified stock options and 8,250 restricted stock units to three new non-executive employees who joined in March 2025.
The stock options will vest 25% after one year, with the remaining shares vesting monthly over three years. The restricted stock units will vest one-third annually over three years. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company specializing in therapeutic resistance treatments, has announced its participation in two major investor conferences in April 2025.
The company will present at two events:
- Needham's 24th Annual Healthcare Conference - Company overview presentation scheduled for Monday, April 7, 2025, at 1:30 p.m. ET
- Stifel 2025 Virtual Targeted Oncology Forum - Fireside chat participation on Wednesday, April 9, 2025, at 2:00 p.m. ET
Both events will be webcasted and accessible through ORIC's investor relations website, with replays available for 90 days post-event.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that preclinical data for ORIC-944, their PRC2 inhibitor for prostate cancer treatment, will be presented at the 2025 AACR Annual Meeting in Chicago (April 25-30, 2025).
The preclinical results show ORIC-944 as a potent, selective, and orally bioavailable allosteric PRC2 inhibitor with properties supporting once-daily dosing. The drug demonstrated robust PRC2 inhibition in prostate cancer models, enhancing luminal cell state and increasing androgen receptor (AR) signaling. The treatment restricts cellular plasticity and creates an AR-dependent state, showing synergy with AR pathway inhibitors (ARPIs) in both ARPI-sensitive and resistant settings.
A phase 1b trial combining ORIC-944 with ARPIs is currently ongoing in metastatic prostate cancer (NCT05413421).